Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 1.00 |
| ▸ | PPARG | P37231 | 18/20 | 1.00 |
| ▸ | RARG | P13631 | 10/20 | 0.78 |
| ▸ | RXRB | P28702 | 6/20 | 0.64 |
| ▸ | RXRG | P48443 | 6/20 | 0.64 |
| ▸ | RARA | P10276 | 5/20 | 0.64 |
| ▸ | RARB | P10826 | 5/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706005 | 1.00 | RXRA (1.00) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL6705849 | 0.90 | RXRA (0.82) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL6705845 | 0.90 | RXRA (0.82) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL4151577 | 0.88 | RXRA (1.00) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL4151576 | 0.88 | RXRA (1.00) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL726448 | 0.88 | RXRA (1.00) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL6707085 | 0.81 | RXRA (0.67) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL6707087 | 0.81 | RXRA (0.67) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL726354 | 0.79 | RXRA (1.00) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL4138521 | 0.79 | RXRA (1.00) | RXRAPPARGRARGRXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248919-A1 | Fluorinated trienes and their use as rxr modulators | ELI LILLY AND COMPANY | 2004-12-09 | — | — | US | claimed |
| EP-1368296-A1 | FLUORINATED TRIENES AND THEIR USE AS RXR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | claimed |
| WO-2002072528-A1 | FLUORINATED TRIENES AND THEIR USE AS RXR MODULATORS | ELI LILLY AND COMPANY (US) | 2002-09-19 | — | — | WO | claimed |
| US-20040248919-A1 | Fluorinated trienes and their use as rxr modulators | ELI LILLY AND COMPANY | 2004-12-09 | — | — | US | disclosed |
| EP-1368296-A1 | FLUORINATED TRIENES AND THEIR USE AS RXR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002072528-A1 | FLUORINATED TRIENES AND THEIR USE AS RXR MODULATORS | ELI LILLY AND COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248919-A1 | Fluorinated trienes and their use as rxr modulators | RXRA, THRA, RXRB | RXRA 1/4885PPARG 20/4885RARG 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.